abstract BACKGROUND AND OBJECTIVES: Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome (CRMS) describes asymptomatic infants with a positive cystic fibrosis (CF) newborn screen (NBS) but inconclusive diagnostic testing for CF. Little is known about the epidemiology and outcomes of CRMS. The goal of this study was to determine the prevalence, clinical features, and short-term outcomes of infants with CRMS.
WHAT'S KNOWN ON THIS SUBJECT:
Little is known about the prevalence or outcomes of infants with indeterminate diagnostic results after a positive cystic fibrosis (CF) newborn screen (CF transmembrane conductance regulator-related metabolic syndrome [CRMS] ). Cystic fibrosis (CF) is an autosomalrecessive condition caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. 1 Early diagnosis of CF results in improved nutritional and cognitive outcomes, 2, 3 and as of 2010 CF newborn screening (NBS) has been implemented in every state in the United States. 4 CF is one of the most common causes for a positive NBS test. 5 In the United States, NBS programs are administered at the state level, and the specific NBS algorithm used varies from state to state. 4 All CF NBS algorithms begin with measurement of immunoreactive trypsinogen (IRT) from a dried blood spot. If the IRT is elevated, CFTR gene mutation analysis, a repeat IRT 1 to 2 weeks later, or a combination of these is performed to improve the specificity of the testing. In infants with a positive NBS, measurement of sweat chloride (Cl) is required to establish a CF diagnosis. 1 Like any diseasescreening process, there is the potential for indeterminate results. Infants with an indeterminate diagnosis present a treatment challenge to clinicians and a stress on families. A US Cystis Fibrosis Foundation (CFF) consensus conference proposed the term CFTRrelated metabolic syndrome (CRMS) to describe asymptomatic infants who have a positive CF NBS and indeterminate diagnostic testing. 6 Data on the prevalence, clinical features, and clinical outcomes of infants with CRMS have been limited to small retrospective single-center studies. [7] [8] [9] The US CFF Patient Registry (CFFPR) added CRMS as a diagnostic category in 2010. In this report, we describe the clinical features and short-term outcomes of infants with CRMS and the accuracy of diagnostic classification of CF and CRMS in the CFFPR.
WHAT THIS STUDY ADDS

METHODS
The design of the CFFPR has been previously described. 10 Every CFF-accredited Care Center and Affiliate Program (n = 154) participates in the CFFPR. In March 2010, the CFFPR added CRMS as a separate diagnostic category. A clinical diagnosis of CF or CRMS is entered by the care center staff for each patient. Data collected at clinical encounters include respiratory tract microbiology, growth parameters, lung function measurements, and medication use. There are some data (eg, physical examination findings) that are not entered into the CFFPR. The protocol is reviewed and approved by the local institutional review boards, and parents provide written informed consent for their child's data to be entered into the registry.
The population for this study included all patients in the CFFPR born from 2010 to 2012 whose diagnosis was entered as CF or CRMS (ie, clinical diagnosis) after a positive NBS. We also categorized infants as CF or CRMS (ie, guideline diagnosis) based on the CFF diagnostic criteria 1, 6 by using CFTR mutation classifications from the Clinical and Functional Translation of CFTR Project (CFTR2). [11] [12] [13] CFTR2 has categorized mutations into 1 of 4 categories: (1) CF-causing (eg, F508del), (2) not disease causing (eg, M470V), (3) associated with varying clinical consequences (eg, R117H), and (4) unknown significance (ie, not enough information to make a clear determination). 12 As of July 2014, CFTR2 had evaluated 217 mutations, representing 96% of the known alleles in the CFTR2 database. In this article, we use the term unevaluated to refer to mutations for which the functional significance has not yet been evaluated. The CFF definition of CF in infants with a positive CF NBS test requires a sweat Cl $60 mmol/L or 2 CFTR gene mutations that are known to be disease causing. 1 CRMS is defined as infants with a positive CF NBS and either (1) a sweat Cl between 30 and 59 mmol/L and fewer than 2 CF-causing CFTR mutations or (2) a normal sweat Cl (,30 mmol/L) and 2 CFTR mutations, of which no more than 1 is known to be CF-causing. 6 To derive a guideline definition of CRMS, it was necessary for patients to have adequate sweat Cl and CFTR mutation data to satisfy 1 of the 2 previously mentioned criteria. Also, infants with 2 unevaluated mutations were not assigned a guideline diagnosis because we could not be sure that both mutations will ultimately be found to be disease causing.
We compared the demographics (gender, race, ethnicity) of infants with a guideline diagnosis of CF with those with CRMS. In addition, for all encounters during the first year of life, we examined anthropometric characteristics, health care use, microbiology, and treatments. Differences between patients with CF and patients with CRMS and between subgroups of patients with CRMS were assessed by using x 2 tests for categorical variables and t tests for continuous variables; P values #0.05 were considered statistically significant. All analyses were conducted by using SAS version 9.3 (SAS Institute, Inc, Cary, NC). Means and frequencies are presented with their 95% confidence intervals; nonoverlapping confidence intervals indicate significant differences with P , .05.
We conducted the following secondary analyses. First, we examined the impact of including infants born in 2012 because they did not have a complete year of follow-up. Where available, we examined the intron 8 thymidine repeat (poly T) tract status for patients whose mutation profile was F508del/R117H, as this affects penetrance (ie, R117H/5T is likely to be a disease-causing mutation, whereas R117H/7T or R117H/9T is less likely to be disease causing). 12, 13 For infants with a positive respiratory culture for Pseudomonas aeruginosa (Pa), we examined the proportion of individuals with 2 or more positive cultures. Last, we examined the association between prescription of pancreatic enzyme replacement therapy (PERT) and, where available, fecal elastase (FE) test results.
RESULTS
From 2010 to 2012, 1983 infants diagnosed with CF or CRMS after a positive NBS were entered into the CFFPR, of whom 1731 had a clinical diagnosis of CF and 231 had a clinical diagnosis of CRMS. There were 21 infants whose clinical diagnosis was CFTR-related disorder or CF ruled out; these infants were excluded from the analysis. Table 4 ).
Comparing the guideline diagnosis with the clinical diagnosis (Table 2) , almost all patients with a guideline diagnosis of CF also had a clinical diagnosis of CF. In contrast, 40.8% of patients with a guideline diagnosis of CRMS had a clinical diagnosis of CF. Among patients for whom we had insufficient information to assign a guideline diagnosis, 64.6% had a clinical diagnosis of CF. Table 5 ).
Among infants with a guideline diagnosis of CRMS, those with a clinical diagnosis of CF had significantly more clinic visits and cultures than those with a clinical diagnosis of CRMS (Supplemental Table 6 ). Growth parameters did not differ substantially between the groups. There was a nonsignificant trend toward more cultures that were positive for Pa and other CF-associated airway pathogens among infants with a clinical diagnosis of CF. Infants with a clinical diagnosis of CF were significantly more likely to be prescribed CF-related therapies, especially PERT and dornase alfa but less likely to be prescribed bronchodilators.
We conducted several secondary analyses to assess the robustness of our data and gain further insight into the results. Because the study included data from January 1, 2010, to December 31, 2012, infants born in 2012 did not have a full year of data Infants in the unknown category had insufficient data in the CFFPR to assign an analytic diagnosis.
entered into the CFFPR. Therefore, we performed an analysis excluding infants born in 2012. Not surprisingly, infants with a complete year of data had a higher total number of encounters and cultures. However, similar to infants with a complete year of data, infants with CF were seen more often and had more cultures compared with infants with CRMS.
There were 115 infants with the F508del/R117H mutation profile, 89 with a guideline diagnosis of CRMS and 26 with a guideline diagnosis of CF. Poly T tract data were available for 57.3% of these infants. Among those with poly T tract data, 9.8% were 5T, 78.4% were 7T, 3.9% were 9T, and the remainder was unknown.
Among 7 Ren et al 8 reported their experience with a small cohort (n = 12) of infants with CRMS at a single CF center, and Sermet-Gaudelus et al 9 studied outcomes in CF NBS-positive infants with and without abnormal nasal potential difference measurements. In both studies, there were infants with CRMS who developed features of CF disease. However, the small number of patients studied limited their ability to estimate the incidence of these outcomes and how applicable their findings were to the general population of infants with CRMS. Our study population comes from .100 CF centers across the country, and provides a more comprehensive picture of CRMS in the United States.
Our results indicate that infants with CRMS in general demonstrate normal growth and nutrition, but may have laboratory tests that are concerning for manifestations of CF. Although Staphylococcus aureus and Haemophilus influenzae can be found in the respiratory tract of infants without CF, the incidence of Pa and Stenotrophomonas maltophilia in the first year of life in the CRMS cohort was much higher than that reported in non-CF populations. 15, 16 However, data on the prevalence of these CF-related pathogens in individuals without CF are somewhat limited, and we could not assess the clinical consequences of positive Pa oropharyngeal cultures in this study. We also cannot determine if follow-up of these infants at the CF center potentially exposed them to CF patients who were Pa-positive and contributed to their acquiring Pa in their respiratory tract. Although FE levels were not recorded for all the infants with CRMS in the CFFPR, analysis of the available data suggests that some infants with CRMS may have pancreatic insufficiency and thus have a symptom consistent with a diagnosis of CF or transiently impaired pancreatic function, which does not require lifelong treatment with PERT. 17 Our data show that there are differences in demographics and treatment between infants with CRMS with a normal sweat Cl, 1 diseasecausing CFTR mutation, and 1 mutation of uncertain or variable significance (47% of the guideline diagnosed CRMS cohort) compared with infants with CRMS with an intermediate sweat Cl concentration. However, both groups showed a greater than expected prevalence of Pa-positive respiratory cultures, suggesting that risk of acquiring Pa may be higher in infants with CRMS than in the general population regardless of their sweat Cl concentration and emphasizing the need for good infection-prevention strategies. 18, 19 A common genotype identified in our study was F508del/ R117H, a finding that also has been reported in other studies of CRMS. 8, 9 Among those with poly T data available, similar to previous studies, we found that 7T was the most common polymorphism identified in infants with CRMS. Although R117H with 7T is considered unlikely to act as a disease-causing mutation, in some cases it can be associated with clinical symptoms of CF. 4 
CONCLUSIONS
We have conducted the largest multicenter study to date of the clinical features and initial outcomes of infants with CRMS. CRMS is a common outcome arising from CF NBS, and although the vast majority of infants with CRMS are healthy, a small proportion of them may develop manifestations of CF. Our results will be helpful to clinicians who need to counsel and care for infants with CRMS and their families. They also support the CFF CRMS guidelines, which recommend that these infants should be monitored for the development of clinical features of CF, 6 although good infection-control practices should be in place to avoid potentially increasing their risk for Pa acquisition. Education of CF clinicians on the CF and CRMS definition and a follow-up consensus conference on diagnosis and treatment of CF and CRMS also should be considered to address issues of potential misclassification.
